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Objective: The aim of the present study was to evaluate the effect of the glucagon-like
peptide-1 analog liraglutide on weight loss in overweight and obese women with polycystic
ovary syndrome (PCOS).
Methods: In an observational study, 84 overweight or obese women with PCOS were
treated with liraglutide. Baseline characteristics and weight changes at clinical follow-up
were recorded. Main outcome measures were absolute and relative weight loss.
Results: In overweight or obese women with PCOS treated with liraglutide for a mini-
mum of 4 weeks, a mean weight loss of 9.0 kg (95% CI: 7.8–10.1, p<0.0001) and a mean
decrease in BMI of 3.2 kg/m2 (95% CI: 2.8–3.6, p<0.0001) were found. A weight loss
of more than 5 and 10% of baseline weight was seen in 81.7 and 32.9% of patients,
respectively. The mean duration of treatment with liraglutide was 27.8 weeks (SD 19.2).
Conclusion: Treatment with liraglutide in combination with metformin and lifestyle inter-
vention resulted in a significant weight loss in overweight and obese women with PCOS,
indicating that liraglutide may be an effective alternative for weight loss in this group of
patients. However, larger placebo-controlled studies are needed to confirm this.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrine
disorder in women of reproductive age, with a reported preva-
lence of 6–15% depending on the population studied and the
diagnostic criteria used (1–3). According to the Rotterdam cri-
teria introduced in 2003, PCOS is defined by at least two of
the following: oligo-amenorrhea, clinical or biochemical hyper-
androgenism and polycystic ovaries on ultrasound (4). A large
proportion of women with PCOS are overweight or obese, in
particular with abdominal obesity (5). They often have insulin
resistance, compensatory hyperinsulinemia, impaired glucose tol-
erance, and a higher risk of type 2 diabetes (6–8). PCOS is therefore
considered as a prediabetic state. Although PCOS and obesity
are strongly related, the underlying mechanism linking the two
involves a complex pathophysiology. Obesity may play a patho-
genic role in the development of PCOS in susceptible individuals.
Obesity-related insulin resistance and resulting hyperinsulinemia
may cause a decreased sex-hormone binding globulin production
and an increased ovarian androgen production,both of which con-
tribute to the hyperandrogenism. However, this may form a vicious
circle as hyperandrogenism may also contribute to the insulin
resistance by increasing free fatty acid flux to the liver and muscle
through visceral lipolysis and, in addition,by altering muscle struc-
ture toward less insulin-sensitive muscle fibers (5). In addition,
PCOS is associated with dyslipidemia and endothelial dysfunction
Abbreviations: BMI, body mass index; CI, confidence interval; GLP-1, glucagon-like
peptide-1; PCOS, polycystic ovary syndrome; SD, standard deviation.
(9, 10). The most pronounced metabolic abnormalities are seen
in women with hyperandrogenism and obesity, especially central
obesity (8, 11).
Even a modest weight loss in overweight or obese women with
PCOS reduces insulin resistance, hyperinsulinemia, and hyperan-
drogenism and increases sex-hormone binding globulin produc-
tion (12–14), thereby improving hirsutism, menstrual cyclicity,
ovulation rates, and fertility. Especially, loss of intra-abdominal
fat is associated with resumption of ovulation (15). Furthermore,
weight loss has beneficial effects on cardiovascular risk factors
such as dyslipidemia and blood pressure (12). Therefore, weight
reduction is essential in overweight and obese women with PCOS.
Liraglutide,a glucagon-like peptide-1 (GLP-1) analog with 97%
structural homology to human GLP-1 is used in the treatment of
type 2 diabetes. GLP-1 is a gut hormone of the incretin family that
enhances glucose-stimulated insulin secretion, inhibits glucagon
secretion, delays gastric emptying, and reduces food intake and
appetite. In type 2 diabetes, liraglutide significantly lowers HbA1c
and, in addition, reduces body weight (16). A recent meta-analysis
concluded that GLP-1 receptor agonists not only had a significant
effect on weight loss in overweight type 2 diabetic patients but also
in non-diabetic overweight persons (17). Only one smaller study
has investigated the effect of liraglutide in PCOS patients reporting
a significantly greater weight loss with liraglutide in combination
with metformin than metformin alone (18). Furthermore, a ben-
eficial effect on blood pressure and cholesterol levels has been
observed with GLP-1 analogs (16, 17).
Given that PCOS is a frequent condition and weight loss is
essential but difficult to achieve, it is important to study if the effect
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on body weight reported in other studies can be confirmed in a
selected population of PCOS patients, especially since liraglutide
is not currently approved for weight reduction. In this study, we
therefore investigated the effect of liraglutide on weight reduction
in a larger cohort of PCOS patients.
MATERIALS AND METHODS
The study population comprises all overweight or obese women
starting treatment with liraglutide in the period August 2010 to
January 2012 in a private gynecology and fertility clinic. The fol-
lowing variables were recorded: date of first prescription, age, body
weight at start of treatment, height, weight loss at clinical follow-
up, and dose of liraglutide. Patients were all diagnosed with PCOS
according to the Rotterdam criteria, were overweight or obese,
and had failed to lose any weight after 6 months with metformin
and life style intervention. The intervention consisted of a low-
glycemic diet with no caloric restriction, guidance by a dietitian,
and a recommendation of 45 min of moderate exercise for a min-
imum of three times per week. Treatment with metformin was
given due to insulin resistance and was therefore continued after
start of liraglutide. The procedures of the study were in accordance
with the Helsinki Declaration, and all patients were informed of
the off-label use of liraglutide and gave written informed consent.
Duration of treatment was calculated in full weeks from date
of prescription to discontinuation of treatment or date of last reg-
istered weight loss for patients still being treated. Body weight
and weight loss were self-reported. In patients who temporarily
stopped treatment and gained weight in the pause, weight loss was
calculated as net weight loss over the entire period. Starting dose
was 0.6 mg given as a subcutaneous injection once daily. Dose was
increased if no effect on weight (i.e., weight loss 0 kg) and no side
effects, initially to 1.2 mg and later to 1.8 mg.
Descriptive characteristics are reported as mean and standard
deviation (SD). Mean value with corresponding 95% confidence
interval for changes in body weight and BMI was estimated using
Student’s paired t -test. Level of statistical significance was set
at p< 0.05 and all p-values were two-sided. Data analysis was
conducted in SAS, version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
A total of 105 overweight or obese women with PCOS had a pre-
scription of liraglutide. We excluded four patients who never used
the prescription. Of the 101 patients starting on liraglutide, four
patients (4.0%) were excluded because of discontinuation of treat-
ment due to side effects after less than 4 weeks, eight patients
(7.9%) were excluded because of missing data, and finally five
patients (5.0%) were lost to follow-up after <4 weeks and were
excluded, leaving 84 patients for analysis (Figure 1).
Mean age at start of treatment was 35.5 years (SD 7.9). The
patients had a mean body weight at baseline of 98.9 kg (SD 17.0)
(Table 1). For two patients, no data on baseline weight could be
obtained, thus BMI could not be calculated. Of the remaining
82 women, 67 (81.7%) were obese defined as BMI≥ 30 and 15
(18.3%) were overweight with BMI between 25 and 30. Mean BMI
at baseline was 35.0 kg/m2 (SD 6.0). Mean duration of treatment
was 27.8 weeks (SD 19.2). Twenty women (23.8%) were trying to
lose weight prior to fertility treatment and six women (7.1%) had
FIGURE 1 | Overview of women included in the study.
previously been treated for infertility. Two patients (2.4%) were
diagnosed with diabetes.
Overall, we observed a significant weight loss in women with
PCOS after treatment with liraglutide, the mean weight loss being
9.0 kg (95% CI: 7.8–10.1, p< 0.0001). Likewise, a significant mean
decrease in BMI of 3.2 kg/m2 (95% CI: 2.8–3.6, p< 0.0001) was
found (Table 1). Two patients lost no weight, but no patients expe-
rienced a net weight gain. In all, 67 women (81.7%) lost more than
5% and 27 women (32.9%) lost more than 10% of their baseline
weight. The mean relative weight loss was 9.4% (95% CI: 8.2–10.6,
p< 0.0001) of baseline weight.
A dose of 1.8 mg was reached at some point during treatment in
52/84 (61.9%) patients. As interval to increase in dose differed sub-
stantially among patients and some patients had multiple increases
and decreases, no comparisons between dose groups have been
made.
A total of 50/84 patients (59.5%) were treated for a mini-
mum of 20 weeks. When restricting analysis to patients treated
for 20 weeks or more, mean weight loss was 10.9 kg (95% CI:
9.4–12.5, p< 0.0001) and mean decrease in BMI was 3.9 kg/m2
(95% CI: 3.3–4.4, p< 0.0001) after a mean duration of 39.1 weeks
(SD 17.0). Figure 2 shows weight loss in relation to duration of
treatment.
Treatment with liraglutide was terminated for the following rea-
sons: achieving the desired weight loss in 10 women (11.9%), side
effects in four women (4.8%), start of fertility treatment or preg-
nancy in five women (6.0%), no further effect of liraglutide in 11
women (13.1%), moving or traveling in two women (2.4%), and in
one woman (1.2%) no reason was given. Six women (7.1%) were
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Table 1 | Changes in body weight and BMI after treatment with liraglutide in overweight and obese women with PCOS.
Baseline After treatment
with liraglutide
Decrease 95% CI p
Body weight (kg) 98.9 (17.0) 89.8 (17.8) 9.0 (5.3) 7.8–10.1 <0.0001
BMI (kg/m2) 35.0 (6.0) 31.8 (6.2) 3.2 (1.9) 2.8–3.6 <0.0001
Values are mean (SD). Student’s paired t-test was used to estimate mean difference from baseline with corresponding 95% confidence intervals (CI) and p-values.
BMI, body mass index.
FIGURE 2 | Scatterplot of the relation between duration of treatment with liraglutide and weight loss with best fitted right line and 95% confidence
interval.
lost to follow after more than 4 weeks of treatment. These women
were included in the analysis with data from their last clinical visit.
The remaining 45 women (53.6%) were still being treated with
liraglutide when conducting the present study.
A total of 19 women (22.6%) reported side effects. Nausea was
reported by six (7.1%), vomiting by one (1.2%), diarrhea by four
(4.8%), constipation by one (1.2%), abdominal pain/discomfort
by six (7.1%), itching by two (2.4%), and discomfort by four
(4.8%). In another four women (4.8%), side effect was not spec-
ified. Dose was reduced in nine women (10.7%) due to side
effects.
DISCUSSION
The prevalence of obesity is increasing worldwide. Due to its
weight reducing effect, the potential role of liraglutide in the treat-
ment of obesity is currently being debated including its role in
PCOS-related obesity (19, 20). In the present study, treatment
with liraglutide in 84 overweight and obese women with PCOS
resulted in a significant weight loss of 9.0 kg. Only one smaller
study has evaluated the effect of liraglutide in PCOS and, in agree-
ment with our findings, showed a beneficial effect on body weight
(18). In a 12-week open-label study of 36 obese women with PCOS,
mean weight losses of 6.5, 3.8, and 1.2 kg with liraglutide 1.2 mg
plus metformin, liraglutide 1.2 mg alone, and metformin alone,
respectively, were reported. Weight loss with combination therapy
was significantly greater than with metformin alone. However,
there were only 11 patients in each of the two groups treated with
liraglutide. A meta-analysis of GLP-1 receptor agonists in type 2
diabetes and obesity, including eight trials using liraglutide, also
demonstrated a positive effect on weight loss (17). In type 2 dia-
betes, mean weight losses of 2.05, 2.45, and 2.8 kg after 52 weeks
of liraglutide 1.2, 1.8, and 26 weeks of liraglutide 1.8 mg in com-
bination with metformin, respectively, have been reported (16, 21,
22). In obese non-diabetic subjects, liraglutide in doses of 1.2, 1.8,
2.4, and 3.0 mg resulted in mean weight losses of 4.8, 5.5, 6.3, and
7.2 kg, respectively, after 20 weeks (23).
In our study, 81.7% of patients lost more than 5% of baseline
weight. In comparison, a 20-week randomized study of liraglutide
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in obese non-diabetic subjects demonstrated a relative weight loss
of 5% or more in 61% of individuals treated with liraglutide in
doses of 1.2–3.0 mg, with a higher proportion achieving this in the
highest dose group (23). In an extension of that trial, 64% of sub-
jects on liraglutide lost >5% of body weight after 1 year and 85%
of these maintained that weight loss after 2 years of treatment (24).
Differences in the magnitude of the effect of liraglutide on
weight loss between studies may be due to differences in study
populations and design. The population in our study is not com-
parable to most trials on liraglutide, which have been done on a
more diverse population with greater mean age and also includ-
ing men. Although, similar weight losses with liraglutide have
been observed in men and women (24), and none of the stud-
ies have reported weight loss in relation to age. All women in
our study were taking metformin simultaneously. Slightly, higher
mean weight reductions have been reported in trials of liraglutide
in combination with metformin than trials of liraglutide alone (21,
22), but no larger studies with direct comparison of liraglutide
monotherapy versus combination therapy with metformin could
be identified. Except for metformin, most antidiabetic drugs are
associated with weight gain potentially augmenting the effect of
liraglutide in studies in diabetic populations. Only two patients in
our study had diabetes. Furthermore, some women in the present
study were referred for infertility and could be more motivated to
make favorable changes in lifestyle in order to improve chance of
pregnancy and possibly also be willing to accept side effects to a
greater extent compared to type 2 diabetics or obese non-diabetics.
Additionally, we excluded patients dropping out before four full
weeks of treatment, whereas most of the above mentioned trials
have been based on analyses of the intention-to-treat population.
Finally, weight loss on liraglutide is dose-dependent with greater
loss with increasing dose (23, 25), and 61.9% of patients in the
present study received a dose of 1.8 mg.
Our results are also in agreement with a study evaluating the
effect of another GLP-1 receptor agonist in PCOS. A 24-week ran-
domized study of exenatide demonstrated a mean weight loss of
3.2, 6.0, and 1.6 kg with monotherapy, combination therapy with
metformin, and metformin alone, respectively, and in both exe-
natide arms was the difference from metformin alone statistically
significant (26). Liraglutide has been shown to decrease HbA1c
more than exenatide, but no difference in weight loss was observed
(25). However, the exenatide study had only 20 patients in each of
the 3 arms and thus had limitations of small sample size and also
a high drop-out rate of 30%.
A large proportion of women with PCOS are overweight or
obese and infertility due to anovulation is common. Significant
improvements in insulin resistance, hyperinsulinemia, dyslipide-
memia, menstrual cyclicity, ovulation rates, and fertility have been
shown with a modest relative weight loss of 5–10% in PCOS
(12–15, 27, 28). Therefore, weight reduction is essential in the
management of PCOS. As 81.7 and 32.9% of patients in the present
study lost more than 5 and 10% of baseline weight, respectively, it
is possible that improvements in these parameters have occurred.
However, we had no information on metabolic and reproduc-
tive changes, and were thus unable to investigate any potential
effect of weight loss in this aspect. Exenatide combined with
metformin in PCOS significantly improved ovulation rates and
metabolic parameters (decreased free androgen index, total cho-
lesterol and trigyceride, increased insulin sensitivity measures) and
reduced abdominal girth compared with metformin alone (26). In
obese non-diabetic subjects, liraglutide has been shown to reduce
the prevalence of prediabetes with 84–96% and the proportion
of patients with metabolic syndrome by more than 60% (23).
Although no significant effect on menstrual frequency and most
metabolic and hormonal parameters were observed in women
with PCOS using liraglutide for 12 weeks, this is possibly due to
the short duration of that study (18).
Gastrointestinal side effects such as diarrhea, vomiting and, in
particular, nausea are common with liraglutide treatment. Nausea
has been reported by 11–48% and vomiting by 4–15% of sub-
jects taking liraglutide, and like the weight reduction it occurs in
a dose-dependent manner (21–25). It could therefore be specu-
lated whether the weight reducing effect of liraglutide could be
ascribed to these side effects. However, nausea mostly occurred
in the first 4–6 weeks of treatment, was transient, and of mild
to moderate intensity (21–25). In the present study, frequency
of side effects was generally low when compared to other stud-
ies of liraglutide. Reasons for this could include a slower dose
titration, but also our exclusion of patients who did not com-
plete 4 weeks of treatment, among these four women with side
effects. Additionally, some women lost to follow-up could have
dropped out because of side effects. Garber et al. found no differ-
ence in weight loss between patients with and without persistent
nausea (defined as ≥7 days) with liraglutide 1.2 and 1.8 mg (21).
Similar results were found in a post hoc analysis of the study by
Astrup et al. where the difference in weight loss between individ-
uals with and without nausea or vomiting was significant only
for the group on liraglutide 3.0 mg (29). Furthermore, the dose-
dependent weight reduction with increasing doses of liraglutide
was maintained both for participants with and without nausea
or vomiting. Finally, weight loss among patients without nau-
sea or vomiting was still significantly greater with liraglutide
than with placebo or orlistat (24). Thus, nausea may increase
weight loss some in high doses of liraglutide, but does not seem
to be a major contributor for the weight reduction seen with
liraglutide.
All patients in our study were taking metformin simultaneously.
Gastrointestinal side effects are also frequent with metformin.
It is therefore noteworthy that studies investigating combina-
tion therapy of liraglutide and metformin did not report higher
frequencies of nausea or vomiting than studies of liraglutide
monotherapy (21, 22).
A limitation of our study is the lack of a placebo group.
Secondly, weight loss was self-reported, potentially reducing the
accuracy of the effect. Furthermore, weight loss from our study
is difficult to compare with studies of a fixed duration because of
great variations in duration of treatment among women in our
study. Treatment duration ranged from 4 to 76 weeks and weight
loss tended to increase with increasing duration of treatment with
liraglutide, probably contributing to the differences in weight loss
between subjects. Most studies have evaluated effect after at least
20 weeks of treatment. We tried to compensate for this by con-
ducting a subgroup analysis restricting duration to 20 weeks or
more, resulting in a slightly higher mean weight loss. In addition,
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all women had initially been treated with metformin and lifestyle
intervention with a low-glycemic diet and exercise for 6 months,
and only women who did not lose any weight on this regimen
were prescribed liraglutide. After starting liraglutide, women were
encouraged to continue the lifestyle intervention. We cannot rule
out that this has contributed to the weight loss or that adher-
ence to lifestyle intervention might have changed. However, we do
not believe this to be the primary explanation for the weight loss.
Finally, the lack of information on improvements in reproductive
and metabolic dysfunction limits assessment of the clinical effect
of weight loss. This should be addressed in future studies.
In summary, the results of this study indicate that liraglutide in
combination with metformin and lifestyle intervention may be an
effective alternative for weight loss in women with PCOS who fail
to lose weight on diet, exercise, and metformin. However, larger
prospective placebo-controlled intervention studies in overweight
and obese women with PCOS are needed to establish the effect on
weight loss. The clinical effect of weight loss on reproductive and
metabolic parameters should be investigated. Finally, studies on
sustainability of the achieved weight loss are needed.
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